Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

288 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines.
Clarke MJ, Mulligan EA, Grogan PT, Mladek AC, Carlson BL, Schroeder MA, Curtin NJ, Lou Z, Decker PA, Wu W, Plummer ER, Sarkaria JN. Clarke MJ, et al. Among authors: sarkaria jn. Mol Cancer Ther. 2009 Feb;8(2):407-14. doi: 10.1158/1535-7163.MCT-08-0854. Epub 2009 Jan 27. Mol Cancer Ther. 2009. PMID: 19174557 Free PMC article.
Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.
Kitange GJ, Mladek AC, Carlson BL, Schroeder MA, Pokorny JL, Cen L, Decker PA, Wu W, Lomberk GA, Gupta SK, Urrutia RA, Sarkaria JN. Kitange GJ, et al. Among authors: sarkaria jn. Clin Cancer Res. 2012 Aug 1;18(15):4070-9. doi: 10.1158/1078-0432.CCR-12-0560. Epub 2012 Jun 6. Clin Cancer Res. 2012. PMID: 22675172 Free PMC article.
Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents.
Agarwal S, Mittapalli RK, Zellmer DM, Gallardo JL, Donelson R, Seiler C, Decker SA, Santacruz KS, Pokorny JL, Sarkaria JN, Elmquist WF, Ohlfest JR. Agarwal S, et al. Among authors: sarkaria jn. Mol Cancer Ther. 2012 Oct;11(10):2183-92. doi: 10.1158/1535-7163.MCT-12-0552. Epub 2012 Aug 13. Mol Cancer Ther. 2012. PMID: 22891038 Free PMC article.
Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
Gupta SK, Mladek AC, Carlson BL, Boakye-Agyeman F, Bakken KK, Kizilbash SH, Schroeder MA, Reid J, Sarkaria JN. Gupta SK, et al. Among authors: sarkaria jn. Clin Cancer Res. 2014 Jul 15;20(14):3730-41. doi: 10.1158/1078-0432.CCR-13-3446. Epub 2014 May 16. Clin Cancer Res. 2014. PMID: 24838527 Free PMC article.
Design and characterization of an economical (192)Ir hemi-brain small animal irradiator.
Grams MP, Wilson ZC, Sio TT, Beltran CJ, Tryggestad EJ, Gupta SK, Blackwell CR, McCollough KP, Sarkaria JN, Furutani KM. Grams MP, et al. Among authors: sarkaria jn. Int J Radiat Biol. 2014 Oct;90(10):936-942. doi: 10.3109/09553002.2014.922719. Epub 2014 Jun 25. Int J Radiat Biol. 2014. PMID: 24844370 Free PMC article.
NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification.
Yoshida Y, Ozawa T, Yao TW, Shen W, Brown D, Parsa AT, Raizer JJ, Cheng SY, Stegh AH, Mazar AP, Giles FJ, Sarkaria JN, Butowski N, Nicolaides T, James CD. Yoshida Y, et al. Among authors: sarkaria jn. Mol Cancer Ther. 2014 Dec;13(12):2919-29. doi: 10.1158/1535-7163.MCT-14-0306. Epub 2014 Oct 13. Mol Cancer Ther. 2014. PMID: 25313012 Free PMC article.
288 results